Aurobindo Pharma Limited — Q3 FY25
Aurobindo Pharma delivered its highest-ever quarterly revenue of INR 7,979 crore in Q3 FY25, driven by robust US base product sales, strong European growth (+23% YoY), and expan...
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
38%Questions answered1Evaded / deflected4Questions audited
Partial answer
High priority
Potential US tariffs on pharma and mitigation strategies
Asked by Shyam Steele
Acknowledged tariff risk but gave no concrete pushback or lobbying specifics.
no specific mitigation detailsvague on lobbying
Read the exchange
Question
I just want to understand there's a potential tariff on pharmaceuticals. So as a company, as an industry, what are some of the pushbacks that we give like a lobby back to the U.S. government?
Swami Iyer, CEO Aurobindo Pharma USA
As yet, we don't know what's the final outcome. We don't know what the tariff is. There's a lot of noise right now. We would continue to import from India. We have built up good infrastructure in the U.S. We have a data plan that's coming up. And we also have the Puerto Rico plan.
Partial answer
Medium priority
ROCE on US investments vs corporate averages
Asked by Shyam Steele
Explained ramp-up will improve ROCE but gave no quantitative target or timeline.
no specific ROCE targetdeferred to future
Read the exchange
Question
In terms of ROCEs, are these investments or is there a way to make sure these ROCEs are higher than where our corporate averages are?
Satakarni Makkapati, CEO Aurobindo Pharma
The units like Penicillin or Eugia or China, these are all in the ramping up and then incurring losses. Once the full ramp-up is taking place, you see it will get converted into positive, which will help us to improve the ROCE.
Partial answer
High priority
Sustainability of gross margins at 58-59%
Asked by Vivek Agarwal
Confirmed retention but gave no quantitative outlook or details on moving parts.
no specific margin guidancevague on sustainability
Read the exchange
Question
Currently, we are in the range of around 58%-59% over the last few quarters. Will you be able to maintain this margin, let's say, around one to two years down the line?
Subramanian Santhanam, CFO Aurobindo Pharma
Already all these products, PenG and other things should start contributing, which will help to retain the gross margin certainly.
Declined
High priority
Can gross margins move up meaningfully?
Asked by Vivek Agarwal
Refused to answer, deferred to future call.
deferred to next quarter
Read the exchange
Question
I'm just trying to understand, can this margin move up from here on meaningfully, or you will be able to maintain this margin?
Subramanian Santhanam, CFO Aurobindo Pharma
I think let's park this question for the next call.